Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina : Cross-sectional and longitudinal studies
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd..
Background: Sarajevo Canton in the Federation of Bosnia and Herzegovina has recorded several waves of high SARS-CoV-2 transmission and has struggled to reach adequate vaccination coverage. We describe the evolution of infection- and vaccine-induced SARS-CoV-2 antibody response and persistence.
Methods: We conducted repeated cross-sectional analyses of blood donors aged 18-65 years in Sarajevo Canton in November-December 2020 and 2021. We analyzed serum samples for anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies. To assess immune durability, we conducted longitudinal analyses of seropositive participants at 6 and 12 months.
Results: One thousand fifteen participants were included in Phase 1 (November-December 2020) and 1152 in Phase 2 (November-December 2021). Seroprevalence increased significantly from 19.2% (95% CI: 17.2%-21.4%) in Phase 1 to 91.6% (95% CI: 89.8%-93.1%) in Phase 2. Anti-S IgG titers were significantly higher among vaccinated (58.5%) than unvaccinated infected participants across vaccine products (p < 0.001), though highest among those who received an mRNA vaccine. At 6 months, 78/82 (95.1%) participants maintained anti-spike seropositivity; at 12 months, 58/58 (100.0%) participants were seropositive, and 33 (56.9%) had completed the primary vaccine series within 6 months. Among 11 unvaccinated participants who were not re-infected at 12 months, anti-S IgG declined from median 770.1 (IQR 615.0-1321.7) to 290.8 (IQR 175.7-400.3). Anti-N IgG antibodies waned earlier, from 35.4% seropositive at 6 months to 24.1% at 12 months.
Conclusions: SARS-CoV-2 seroprevalence increased significantly over 12 months from end of 2020 to end of 2021. Although individuals with previous infection may have residual protection, COVID-19 vaccination is vital to strengthening population immunity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 17(2023), 8 vom: 23. Aug., Seite e13182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Musa, Sanjin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bosnia and Herzegovina |
|---|
| Anmerkungen: |
Date Completed 28.08.2023 Date Revised 14.12.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT05124535 Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.13182 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361201753 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361201753 | ||
| 003 | DE-627 | ||
| 005 | 20231227131512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.13182 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM361201753 | ||
| 035 | |a (NLM)37621919 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Musa, Sanjin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina |b Cross-sectional and longitudinal studies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2023 | ||
| 500 | |a Date Revised 14.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT05124535 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. | ||
| 520 | |a Background: Sarajevo Canton in the Federation of Bosnia and Herzegovina has recorded several waves of high SARS-CoV-2 transmission and has struggled to reach adequate vaccination coverage. We describe the evolution of infection- and vaccine-induced SARS-CoV-2 antibody response and persistence | ||
| 520 | |a Methods: We conducted repeated cross-sectional analyses of blood donors aged 18-65 years in Sarajevo Canton in November-December 2020 and 2021. We analyzed serum samples for anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies. To assess immune durability, we conducted longitudinal analyses of seropositive participants at 6 and 12 months | ||
| 520 | |a Results: One thousand fifteen participants were included in Phase 1 (November-December 2020) and 1152 in Phase 2 (November-December 2021). Seroprevalence increased significantly from 19.2% (95% CI: 17.2%-21.4%) in Phase 1 to 91.6% (95% CI: 89.8%-93.1%) in Phase 2. Anti-S IgG titers were significantly higher among vaccinated (58.5%) than unvaccinated infected participants across vaccine products (p < 0.001), though highest among those who received an mRNA vaccine. At 6 months, 78/82 (95.1%) participants maintained anti-spike seropositivity; at 12 months, 58/58 (100.0%) participants were seropositive, and 33 (56.9%) had completed the primary vaccine series within 6 months. Among 11 unvaccinated participants who were not re-infected at 12 months, anti-S IgG declined from median 770.1 (IQR 615.0-1321.7) to 290.8 (IQR 175.7-400.3). Anti-N IgG antibodies waned earlier, from 35.4% seropositive at 6 months to 24.1% at 12 months | ||
| 520 | |a Conclusions: SARS-CoV-2 seroprevalence increased significantly over 12 months from end of 2020 to end of 2021. Although individuals with previous infection may have residual protection, COVID-19 vaccination is vital to strengthening population immunity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bosnia and Herzegovina | |
| 650 | 4 | |a SARS‐CoV‐2 | |
| 650 | 4 | |a cross‐sectional study | |
| 650 | 4 | |a longitudinal study | |
| 650 | 4 | |a seroprevalence | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Catovic Baralija, Elma |e verfasserin |4 aut | |
| 700 | 1 | |a Ivey Sawin, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Nardone, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Palo, Mirza |e verfasserin |4 aut | |
| 700 | 1 | |a Skocibusic, Sinisa |e verfasserin |4 aut | |
| 700 | 1 | |a Blazevic, Mia |e verfasserin |4 aut | |
| 700 | 1 | |a Cilovic Lagarija, Seila |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmetovic-Karic, Gorana |e verfasserin |4 aut | |
| 700 | 1 | |a Ljuca, Alma |e verfasserin |4 aut | |
| 700 | 1 | |a Dostovic-Halilovic, Sanela |e verfasserin |4 aut | |
| 700 | 1 | |a Nedic, Rozalija |e verfasserin |4 aut | |
| 700 | 1 | |a Subissi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Rawi |e verfasserin |4 aut | |
| 700 | 1 | |a Boshevska, Golubinka |e verfasserin |4 aut | |
| 700 | 1 | |a Bergeri, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Pebody, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Vaughan, Aisling |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 17(2023), 8 vom: 23. Aug., Seite e13182 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:8 |g day:23 |g month:08 |g pages:e13182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.13182 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 8 |b 23 |c 08 |h e13182 | ||